{"id":69034,"date":"2026-06-29T20:58:52","date_gmt":"2026-06-29T12:58:52","guid":{"rendered":"https:\/\/flcube.com\/?p=69034"},"modified":"2026-06-29T20:58:54","modified_gmt":"2026-06-29T12:58:54","slug":"fosun-pharmaceutical-approves-hong-kong-ipo-spin-off-of-vaccine-subsidiary-fosun-adgenvax","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69034","title":{"rendered":"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Fosun Pharmaceutical (Group) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>)<\/strong> announced today that its board of directors has approved the <strong>spin-off and listing<\/strong> of its wholly-owned subsidiary, <strong>Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.<\/strong>, on the <strong>Hong Kong Stock Exchange<\/strong>. The move represents a strategic separation of Fosun&#8217;s preventive vaccine business from its broader pharmaceutical operations.<\/p>\n\n\n\n<h2 id=\"h-corporate-structure-amp-strategic-rationale\" class=\"wp-block-heading\">Corporate Structure &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Entity<\/th><th>Role<\/th><th>Strategic Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Fosun Pharmaceutical<\/strong><\/td><td>Parent company<\/td><td>Integrated pharmaceutical platform (innovative drugs, generics, medical devices)<\/td><\/tr><tr><td><strong>Fosun Adgenvax<\/strong><\/td><td>Spin-off subsidiary<\/td><td>Full-chain vaccine enterprise (R&amp;D, manufacturing, commercialization)<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><td>Access to international biotech investors and valuation premium<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-business-profile-amp-capabilities\" class=\"wp-block-heading\">Business Profile &amp; Capabilities<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Industry Experience:<\/strong> Over <strong>two decades<\/strong> of deep involvement in China&#8217;s preventive vaccine industry<\/li>\n\n\n\n<li><strong>Vertical Integration:<\/strong> <strong>Full-chain capabilities<\/strong> spanning research and development, manufacturing, and commercialization<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Established vaccine enterprise with comprehensive infrastructure and regulatory expertise<\/li>\n\n\n\n<li><strong>Geographic Focus:<\/strong> Primarily China market with potential for international expansion<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-product-pipeline-portfolio\" class=\"wp-block-heading\">Product Pipeline Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Disease Area<\/th><th>Development Stage<\/th><th>Market Strategy<\/th><\/tr><\/thead><tbody><tr><td><strong>Rabies<\/strong><\/td><td>Commercial\/Advanced<\/td><td>Core established franchise<\/td><\/tr><tr><td><strong>Influenza<\/strong><\/td><td>Commercial\/Advanced<\/td><td>Seasonal vaccination programs<\/td><\/tr><tr><td><strong>Pneumococcal diseases<\/strong><\/td><td>Mid-to-late stage<\/td><td>High-value pediatric\/adult markets<\/td><\/tr><tr><td><strong>Meningococcal diseases<\/strong><\/td><td>Mid-to-late stage<\/td><td>Public health and private market segments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>diversified and multi-tiered product pipeline<\/strong> is strategically designed to address specific needs across different market segments and population groups, providing revenue stability and growth opportunities.<\/p>\n\n\n\n<h2 id=\"h-market-implications-amp-financial-impact\" class=\"wp-block-heading\">Market Implications &amp; Financial Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valuation Unlocking:<\/strong> Separate listing expected to highlight vaccine business value distinct from parent pharmaceutical operations<\/li>\n\n\n\n<li><strong>Capital Access:<\/strong> Independent funding for pipeline development and manufacturing capacity expansion<\/li>\n\n\n\n<li><strong>Strategic Flexibility:<\/strong> Enhanced ability to pursue partnerships, acquisitions, and international opportunities<\/li>\n\n\n\n<li><strong>Investor Appeal:<\/strong> Pure-play exposure to China&#8217;s growing preventive vaccine market<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> Benefits from China&#8217;s increased focus on domestic vaccine self-sufficiency and public health preparedness<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The spin-off aligns with global trends of biotech carve-outs and reflects Fosun&#8217;s strategy to maximize shareholder value through focused business units with clear investment theses.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding corporate actions, regulatory processes, and market expectations. Actual outcomes may vary based on Hong Kong Stock Exchange approval, market conditions, and regulatory developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600196_20260627_256Z.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20260627_256Z.\"><\/object><a id=\"wp-block-file--media-4a7194c8-0db7-42ce-aafb-5ce6c37fc755\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600196_20260627_256Z.pdf\">600196_20260627_256Z<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600196_20260627_256Z.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4a7194c8-0db7-42ce-aafb-5ce6c37fc755\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69035,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[3825,159,893,72,892,12],"class_list":["post-69034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-fosun-adgenvax-biopharmaceutical","tag-fosun-pharmaceutical","tag-hkg-2196","tag-ipo","tag-sha-600196","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of directors has approved the spin-off and listing of its wholly-owned subsidiary, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange. The move represents a strategic separation of Fosun&#039;s preventive vaccine business from its broader pharmaceutical operations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69034\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of directors has approved the spin-off and listing of its wholly-owned subsidiary, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange. The move represents a strategic separation of Fosun&#039;s preventive vaccine business from its broader pharmaceutical operations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69034\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T12:58:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-29T12:58:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax\",\"datePublished\":\"2026-06-29T12:58:52+00:00\",\"dateModified\":\"2026-06-29T12:58:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034\"},\"wordCount\":359,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2901.webp\",\"keywords\":[\"Fosun Adgenvax Biopharmaceutical\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"IPO\",\"SHA: 600196\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69034#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69034\",\"name\":\"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2901.webp\",\"datePublished\":\"2026-06-29T12:58:52+00:00\",\"dateModified\":\"2026-06-29T12:58:54+00:00\",\"description\":\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of directors has approved the spin-off and listing of its wholly-owned subsidiary, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange. The move represents a strategic separation of Fosun's preventive vaccine business from its broader pharmaceutical operations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69034\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69034#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of directors has approved the spin-off and listing of its wholly-owned subsidiary, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange. The move represents a strategic separation of Fosun's preventive vaccine business from its broader pharmaceutical operations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69034","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax","og_description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of directors has approved the spin-off and listing of its wholly-owned subsidiary, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange. The move represents a strategic separation of Fosun's preventive vaccine business from its broader pharmaceutical operations.","og_url":"https:\/\/flcube.com\/?p=69034","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-29T12:58:52+00:00","article_modified_time":"2026-06-29T12:58:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69034#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69034"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax","datePublished":"2026-06-29T12:58:52+00:00","dateModified":"2026-06-29T12:58:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69034"},"wordCount":359,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69034#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2901.webp","keywords":["Fosun Adgenvax Biopharmaceutical","Fosun Pharmaceutical","HKG: 2196","IPO","SHA: 600196","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69034#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69034","url":"https:\/\/flcube.com\/?p=69034","name":"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69034#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69034#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2901.webp","datePublished":"2026-06-29T12:58:52+00:00","dateModified":"2026-06-29T12:58:54+00:00","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of directors has approved the spin-off and listing of its wholly-owned subsidiary, Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange. The move represents a strategic separation of Fosun's preventive vaccine business from its broader pharmaceutical operations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69034#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69034"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69034#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2901.webp","width":1080,"height":608,"caption":"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69034#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69034"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69034\/revisions"}],"predecessor-version":[{"id":69037,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69034\/revisions\/69037"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69035"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}